Theranica said today that Omron‘s (TYO:6645) venture arm joined a $35 million Series B financing round to support its remote neuromodulation technology. Israel-based Theranica is developing the Nerivio Migra neurostimulation patch intended to treat migraine headache, which is currently under FDA review. Funding in the round, which was initially announced in March, was led by […]
Omron wins FDA nod for combined blood pressure monitor, EKG
Omron Healthcare (TYO:6645) has won FDA 510(k) clearance for its Blood Pressure Monitor + Echocardiogram device, according to a recently posted FDA release. The device, which was developed in collaboration with AliveCor, allows users to monitor both high blood pressure and atrial fibrillation, which the company said are critical risk factors for stroke. The newly cleared […]
Omron launches HeartGuide watch-based wearable BP monitor
Omron Healthcare (TYO:6645) said late last week that it launched its HeartGuide wearable blood pressure monitor, touting it as the world’s first such device. The HeartGuide is an FDA-cleared, wearable oscillometric blood pressure monitor intended for personal use and styled to function as a wrist watch, the Lake Forest, Ill.-based company said. The device features a cuff […]
Omron’s Q1 healthcare sales rise 9%
Omron (TYO:6645) today said that sales for its healthcare division grew nearly 9% during its fiscal first quarter. Kyoto, Japan-based Omron, whose largest segment is its industrial automation business, said healthcare sales rose 8.5% to ¥27.9 billion, or roughly $250.2 million, “stemming from favorable sales of blood pressure monitors, nebulizers and low-frequency therapy equipment.” Overall profits […]
AngioDynamics CEO DeVivo out, ex-Covidien exec Clemmer in | Personnel Moves for April 4, 2016
1. AngioDynamics CEO DeVivo is out, ex-Covidien exec Clemmer is in AngioDynamics (NSDQ:ANGO) said today that president & CEO Joseph DeVivo stepped down to “pursue other interests” and was replaced by ex-Covidien bigwig James Clemmer, effective today. DeVivo joined Latham, N.Y.-based AngioDynamics in September 2011. “We thank Joe for his contributions and commitment to AngioDynamics over […]
NeuroMetrix soars on Japanese market approval of diabetes test
NeuroMetrix (NSDQ:NURO) got a major Wall Street boost today after announcing Japanese market approval for its NC-stat DPNCheck test for diabetic peripheral neuropathy.
Diabetes: NeuroMetrix gains on Chinese distribution deal
NeuroMetrix (NSDQ:NURO) said it inked a deal with Omron Medical Devices, a subsidiary of Omron Healthcare China, for the distribution rights to NeuroMetrix’s NC-stat DPNCheck in China.
MassDevice Network
@MassDevice
LinkedIn
YouTube